Regulation of CD4⁺NKG2D⁺ Th1 Cells in Patients with Metastatic Melanoma Treated with Sorafenib: Role of IL-15Rα and NKG2D Triggering

Ana I. Romero¹,⁷, Nathalie Chaput¹,⁷,⁸, Vichnou Poirier-Colame¹,⁷,⁸, Sylvie Rusakiewicz¹,⁷,⁸, Nicolas Jacquelt¹,⁷,⁸, Kariman Chaba¹,⁷, Erwan Mortier¹⁰, Yannick Jacques¹⁰, Sophie Calliat-Zucman¹¹, Caroline Flamant¹,⁷, Anne Caignard¹², Meriem Messaoudene¹², Anne Aupérin⁷, Philippe Vielh⁶, Philippe Dessen¹,⁴, Camillo Porta¹⁴, Christine Mateus³,⁵, Maha Ayyoub⁹, Danila Valmori⁹, Alexander Eggermont¹, Caroline Robert³,⁵, and Laurence Zitvogel¹,⁷,⁸,¹³

Abstract
Beyond cancer-cell intrinsic factors, the immune status of the host has a prognostic impact on patients with cancer and influences the effects of conventional chemotherapies. Metastatic melanoma is intrinsically immunogenic, thereby facilitating the search for immune biomarkers of clinical responses to cytotoxic agents. Here, we show that a multi-tyrosine kinase inhibitor, sorafenib, upregulates interleukin (IL)-15Rα in vitro and in vivo in patients with melanoma, and in conjunction with natural killer (NK) group 2D (NKG2D) ligands, contributes to the Th1 polarization and accumulation of peripheral CD4⁺NKG2D⁺ T cells. Hence, the increase of blood CD4⁺NKG2D⁺ T cells after two cycles of sorafenib (combined with temozolomide) was associated with prolonged survival in a prospective phase I/II trial enrolling 63 patients with metastatic melanoma who did not receive vemurafenib nor immune checkpoint–blocking antibodies. In contrast, in metastatic melanoma patients treated with classical treatment modalities, this CD4⁺NKG2D⁺ subset failed to correlate with prognosis. These findings indicate that sorafenib may be used as an "adjuvant" molecule capable of inducing or restoring IL-15Rα/IL-15 in tumors expressing MHC class I–related chain A/B (MICA/B) and on circulating monocytes of responding patients, hereby contributing to the bioactivity of NKG2D⁺ Th1 cells. Cancer Res; 74(1); 68–80. © 2013 AACR.
In parallel, attempts to harness antitumor immunity have progressively led to therapeutic success in melanoma (10). Anti-CTLA-4 antibodies alone or together with peptide-based vaccination or with DTIC significantly prolonged survival of stage III/IV melanoma in two phase III trials (10, 11). One surmises that in patients responding to immunotherapy, tumor- and/or vaccine-specific T cells reset local tumor micro-environment and convert immune tolerance into immune-related tumor destruction (12).

Because vaccines showed some unexpected efficacy after tumor progression with cytotoxic compounds (13, 14), a new concept emerged whereby the host immune system could contribute to the beneficial effects of cytotoxic compounds (15). Indeed, the outcome of chemotherapy can be influenced by the host immune system at multiple levels. Chemotherapy can kill cancer cells in a way that they elicit an immune response (16) or, alternatively, increase their susceptibility to immune attack (17). In addition, chemotherapy can stimulate antitumor immune effectors either directly (by activating effector or dendritic cells) or indirectly by subverting immunosuppressive mechanisms (18, 19). Hence, a recent report pointed out that patients with metastatic melanoma responding to DTIC exhibit a stromal and immune signature, defined by hallmarks of T-cell infiltration and MHC class II expression (20).

A number of immune effectors, including dendritic cells, T cells, and natural killer (NK) cells, have been involved in natural or therapy-induced tumor immunosurveillance in mice (21, 22). The NK group 2D (NKG2D), a lectin-like activating receptor, markedly influences IFN-γ release and cytotoxic responses upon tumor recognition, exerting selective pressure on transformed cells (23). A large body of preclinical work highlighted the beneficial role of the activating receptor NKG2D in immunosurveillance against cancer (24, 25). In most instances, NKG2D-induced effects are mediated through NK or CD8+ effector T cells. Here, we unveil the immunomodulatory role of a multi-tyrosine kinase inhibitor, sorafenib, on a rare subset of circulating (and intratumoral) CD4+CD8-CD8αdimNKG2D+ T cells prone to secrete Th1 cytokines upon cotriggering of CD122 (IL-2/IL-15Rβ) chain and NKG2D receptors. Indeed, sorafenib induced the upregulation of interleukin (IL)-15Rα expression on tumor cells in vitro and in vivo, and/or on circulating monocytes in metastatic melanoma (cotreated with temozolomide) in a phase I/II prospective trial. In patients with metastatic melanoma, melanoma expressed high intrinsic levels of MHC class I–related chain A/B (MICA/B) molecules. Patients developing enhanced frequencies of CD4+ NKG2D+ T cells after two cycles of sorafenib exhibited prolonged survival. Of note, such CD4+ NKG2D+ T cells failed to dictate the prognosis in another cohort of metastatic melanoma enrolled in a MAGE3 protein (26) underscoring the immunoregulatory role of sorafenib.

Materials and Methods

**Patients and treatment plan**

**SORAFTEM.** Sixty-three patients older than 18 years of age, with histologically confirmed metastatic or unresectable melanoma, measurable disease, an Eastern Cooperative Oncology Group performance status less than 2, with adequate hematologic, renal, hepatic, and coagulopathic functions, were included in a phase I/II investigator-sponsored study SORAFTEM (European Union Drug Regulating Authorities clinical trial EudraCT 2007-000527-18). The number of prior therapies is summarized in Table 1. Patients had discontinued their earlier systemic therapy at least 4 weeks before entering the trial. Previous brain radiotherapy was allowed, provided patients were not clinically symptomatic. The study protocol

<table>
<thead>
<tr>
<th>Table 1. Characteristics of patients (n = 63)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gender (male/female)</strong></td>
</tr>
<tr>
<td><strong>Age (mean ± SD) [range]</strong></td>
</tr>
<tr>
<td><strong>Type</strong></td>
</tr>
<tr>
<td>SSM</td>
</tr>
<tr>
<td>Nodular</td>
</tr>
<tr>
<td>Lentigo maligna</td>
</tr>
<tr>
<td>Acral lentigious</td>
</tr>
<tr>
<td>Mucosal</td>
</tr>
<tr>
<td>Ocular</td>
</tr>
<tr>
<td>Other</td>
</tr>
<tr>
<td><strong>Metastasis (56 patients)</strong></td>
</tr>
<tr>
<td>Number of metastasis lesions per patient (mean ± SD)</td>
</tr>
<tr>
<td><strong>Metastatic sites</strong></td>
</tr>
<tr>
<td>Nodes</td>
</tr>
<tr>
<td>Liver</td>
</tr>
<tr>
<td>Lung</td>
</tr>
<tr>
<td>Peritoneum</td>
</tr>
<tr>
<td>Skin</td>
</tr>
<tr>
<td>Bone</td>
</tr>
<tr>
<td>Muscle</td>
</tr>
<tr>
<td><strong>LDH level U/L (mean ± SD)</strong></td>
</tr>
<tr>
<td>LDH ≤ 250 U/L</td>
</tr>
<tr>
<td>LDH &gt; 250 U/L</td>
</tr>
<tr>
<td>ND</td>
</tr>
<tr>
<td><strong>Treatment schedule</strong></td>
</tr>
<tr>
<td>sorafenib 400 mg/d, temozolomide 100 mg/m²</td>
</tr>
<tr>
<td>sorafenib 400 mg/d, temozolomide 150 mg/m²</td>
</tr>
<tr>
<td>sorafenib 800 mg/d, temozolomide 150 mg/m²</td>
</tr>
<tr>
<td><strong>Previous chemotherapy</strong></td>
</tr>
<tr>
<td>No</td>
</tr>
<tr>
<td>One line</td>
</tr>
<tr>
<td>Two lines</td>
</tr>
<tr>
<td>Three lines</td>
</tr>
<tr>
<td>Four lines</td>
</tr>
<tr>
<td>3-month evaluation</td>
</tr>
<tr>
<td>Responders</td>
</tr>
<tr>
<td>Nonresponders</td>
</tr>
</tbody>
</table>

*Abbreviations: SSM, spreading superficial melanoma; ND, not determined.*
was approved by the Institutional Review Boards at the University of Kremlin Bicêtre (Paris, France) and Institut Gustave Roussy (Villejuif, France). All patients provided informed consent before enrollment. The treatment plan is outlined in Supplementary Fig. S1. Stage III and IV melanoma-bearing patients were enrolled from 2006 to 2009 in a dose-escalating phase I followed by a phase II extension cohort at the maximum-tolerated dose trial testing the efficacy of the combinatorial regimen of temozolomide (Schering Plough; 100–150 mg/m² daily for 7 days every 2 weeks) and sorafenib (Bayer; 400–800 mg twice daily without interruption). Therapy was continued until disease progression or intolerable toxicity. Response assessments consisted of physical examination every 4 weeks together with computed tomography scans of the chest, abdomen, and pelvis every 8 weeks. Patients were assessed by an investigator using the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines 1.1. Responses were confirmed by follow-up radiographic evaluation 4 weeks after the initial response criteria were met. BRAF mutations were determined according to technical methods previously described (9). The primary endpoint of the trial was the efficacy of the treatment at 3 months. Patients were classified as objective response or stabilization (called “responders” henceforth) versus progressive disease or death (PD; called “non-responders” henceforth).

**MAGE3 protein–based vaccines.** The details about patient characteristics, protocol description, and survival have been previously reported by Kruit and colleagues (26). CD4 \(^{+}\) NKG2D \(^{+}\) T cells were analyzed at the beginning before vaccine inoculation (1 month after relapse with conventional therapies) and correlated with OS.

**NY-ESO-1 vaccine trial.** Prevaccine peripheral blood samples were collected from patients with malignant melanoma, sarcoma, breast, and ovarian cancer enrolled in a clinical trial of vaccination with recombinant NY-ESO-1, Montanide ISA 51, and CpG 7909 (27) upon informed consent and approval by the Institutional Review Board of Columbia University Medical Center (New York, NY).

**Immunohistochemistry studies**

Paraffin-embedded tumor tissues were first dehydrated and then treated with hydrogen peroxide (H\(_{2}\)O\(_{2}\); DAKO) for neutralizing endogenous peroxidase and Serum Free Protein Block (DAKO) to prevent nonspecific binding. After blocking, primary antibody, anti-MICA/B (SR99; a kind gift from Sophie Caillat-Zucman, INSERM, U1016, Saint Vincent de Paul Hospital, Paris, France) was applied. Binding specificity was controlled by immunoglobulin G (IgG)-isotype controls (Dako). For visualization, EnVision anti-mouse (DAKO) horseradish peroxidase–conjugated streptavidin was applied, followed by the chromogen 3,3'-diaminobenzidine/H\(_{2}\)O\(_{2}\) (DAB; DAKO). Immunostained sections were counterstained very briefly with Mayer’s Hemalaun, dehydrated, and cleared with xylene, before covered with mounting medium (toluene-based) and coverslips (DAKO). For staining of anti-CD3 (polyclonal rabbit, 1:150; DAKO), anti-CD4 (1:20; Novocastra), and anti-CD8 (1:25; Novocastra), the Benchmark system was used. For detection of IL-15Rα, primary antibody (AF247; R&D Systems) was applied at 10 μg/ml after blocking, and anti-goat IgG Alexa Fluor 568 was used at 5 μg/ml as secondary antibody. Isotype-matched antibody was used as negative controls. Samples were mounted in ProLong Gold antifade with 4,6-diamidino-2-phenylindole (DAPI) reagent (Molecular Probes). Fluorescent images were analyzed with an epifluorescent microscope (Zeiss Apotome Microscope).

**PBMC preparations**

Blood samples were drawn from 63 patients before and after each treatment cycle and from 12 healthy volunteers. Peripheral blood mononuclear cells (PBMC) were resuspended in culture medium, i.e., RPMI-1640 (GIBCO Invitrogen), 10% human AB \(^{+}\) serum (Jacques Boy), 1% penicillin/streptavidin (PES; GIBCO Invitrogen), and 1% 2 mmol/L glutamine (GIBCO Invitrogen). Some cells were then stained for flow-cytometric analyses and the rest were resuspended in CryoMaxx medium (PAA Laboratories) for storage in liquid nitrogen.

**Tumor-infiltrating lymphocytes preparations**

Resected lymph node specimens and/or metastatic tissue from 16 patients with metastatic melanoma were analyzed for infiltrating lymphocytes. Tissue samples were placed in dissociation medium, i.e., RPMI-1640, 1% PEST, collagenase IV (8,000 U/mL), hyaluronidase (112,000 IU/mL), and DNAse (12,700 IU/mL), and run on a gentleMACS dissociator (Miltenyi Biotec). The cell samples were then diluted in RPMI-1640 + 10% human AB \(^{+}\) serum, passed through a cell strainer, and centrifuged for 10 minutes at 300 × g. Next, the cells were resuspended in PBS and stained for flow-cytometric analyses. Tumor-coupled specimens of noninvaded lymph node or blood samples were obtained from 10 patients and were analyzed as above.

**Flow cytometry**

Cells were stained with fluorochrome-coupled monoclonal antibodies (mAb), incubated for 20 minutes at 4°C, and washed. Adherent cells were treated with trypsin (Gibco) before the staining step. Cell samples were analyzed using a CyAn ADP 9-Color flow cytometer (Beckman Coulter) or an LSRII flow cytometer (BD Biosciences). For proper compensation, single-stained antibody-capturing heads were used (CompBeads; BD Biosciences). Data were analyzed using FlowJo (TreeStar, Inc.) or FACSDiva (BD Biosciences). For accurate determination of nondiscrete populations, fluorescence-minus-one (FMO) controls were used. For dead-cell discrimination, DAPI (Invitrogen) or the fixable amine-reactive LIVE/DEAD Cell-Stain Kit (Invitrogen) was used. For phenotypic analysis of CD4 \(^{+}\) NKG2D \(^{+}\) T cells, PBMC samples from 11 patients were thawed and resuspended in PBS for 9-color flow-cytometry staining. T cells of interest were identified by CD3, CD4, CD45, CD8, CD14, and NKG2D mAbs and costained with CD28 and CD45RA, or 2B4 and CD161, or IL-15Rα and CX3CR1, or CD25 and CD158 antibodies. The following fluorochrome-coupled anti-human mAbs were used: anti-CD3 (Miltenyi Biotec, BD, Beckman Coulter), anti-CD4 (BD), anti-CD8 (BD, eBioscience), anti-CD14 (BD, eBioscience), anti-CD56 (Beckman Coulter), anti-NKG2D (Miltenyi Biotec), anti-Foxp3
we plated CD4+ Nunc plates with or without anti-CD3 antibody (1 μg/mL), and kept at 37°C, static melanoma were thawed and resuspended in culture medium, and were obtained. PBMCs were collected and enriched for CD4+ T cells and NK cells were cultured overnight in the presence or absence of sMICA (5 μmol/L, Nexavar; Bayer) and temozolomide (50 μmol/L, Temodal; Schering Plough) alone or in combination (protocol without cell death, not shown). The next day, cells were collected and labeled with IL-15Rα polyclonal antibody (H107) followed by an APC-coupled secondary antibody and then stained with DAPI for dead-cell exclusion for flow cytometry analysis. FMO tube was added as negative control, and background staining was excluded with a goat anti-rabbit IgG-APC.

Cytokine production. PBMCs from patients with metastatic melanoma were thawed and resuspended in culture medium, and kept at 37°C, overnight. The next day, cells were enriched for CD4+ T cells and seeded at 10⁶ cells/mL on a flat-bottomed Nunc MaxiSorp 96-well plate, precoated with or without anti-CD3 antibody (0.5 μg/mL), anti-CD122 antibody (1, 10 μg/mL), and anti-NKG2D antibody (4 μg/mL) alone or in combination. After 20 hours of cell culture, the supernatant was collected, concentrated, and analyzed by ELISA for quantification of IFN-γ (BD), IL-2 (BD), TNF-α (BD), IL-17 (R&D Systems), and IL-10 (BD) according to the instruction manuals. For cytokine-release from purified cells, fluorescence-activated cell sorting (FACS)-sorted CD4+ NKG2D+ T cells and NK cells were cultured overnight in the presence or absence of soluble MIC (sMICA; 5 ng/mL; a kind gift from Sophie Caillat-Zucman) and recombinant IL-15 (rIL-15; 5 ng/mL; R&D Systems) alone or in combination. Release of IFN-γ into the supernatant was then measured by ELISA according to the manufacturer’s instructions.

Proliferation. After precoating UV-sterilized MaxiSorp Nunc plates with or without anti-CD3 antibody (1 μg/mL), we plated CD4+ T cells in the presence or absence of sMICA (5 ng/mL) and IL-15 (5 ng/mL) alone or in combination. Cells were then cultured for 5 days, and then harvested for staining with the phycoerythrin (PE)-coupled Ki67, as well as other surface mAbs.

Cytotoxicity. PBMCs were cultured in RPMI/10% SAB with or without 20 ng/mL IL-15 for 4 days. One day before coculture, MEL10 target cells were stained with CMTMR (Invitrogen), seeded on a round-bottomed plate (10,000/well), and treated with or without sorafenib (10 μmol/L). The next day, PBMCs were collected and enriched for CD4 cells before FACSAria III-sorting of NKG2D-positive/negative cells. Target cells were washed with PBS before adding 40,000 sorted T cells to each well and cultured for 20 hours. Floating cells were then transferred to FACSBharga tubes and adherent cells were trypsinized and collected into the same tubes. After centrifugation, the cells were resuspended in PBS and analyzed on a FACSCanto II (BD). For cell death determination, To-Pro-3 (Invitrogen) was added to the tube just before running.

Exposure of melanoma cells to cytotoxic compounds. Eight human melanoma cell lines, M14, M96, MELP, MEL97, MEL888, MT10, and MZ2 were plated and grown confluent in Dulbecco’s Modified Eagle Medium (DMEM) medium (GIBCO Invitrogen) supplemented with 10% FBS (PAA Laboratories), and 1% PEST. Cells were then cultured in the presence or absence of sorafenib (5 μmol/L, Nexavar; Bayer) and temozolomide (50 μmol/L, Temodal; Schering Plough) alone or in combination (protocol without cell death, not shown). The next day, cells were collected and labeled with IL-15Rα polyclonal antibody (H107) followed by an APC-coupled secondary antibody and then stained with DAPI for dead-cell exclusion for flow cytometry analysis. FMO tube was added as negative control, and background staining was excluded with a goat anti-rabbit IgG-APC.

Quantitative reverse transcription PCR for IL-15Rα isoforms. Total cellular RNA was isolated from melanoma cells with the RNeasy Kit (Qiagen). First-strand cDNA was synthesized from 1 μg of total RNA using SuperScript III Reverse Transcriptase (Life Technologies) and random primers according to the manufacturer’s instructions. The quantitative reverse transcription PCR (qRT-PCR) for IL-15Rα (Hs00542604_m1, Hs011986843_m1, and Hs00233692_m1) isoforms and for β2-microglobulin was performed by real-time fluorescence measurement using StepOnePlus System (Life Technologies). The qRT-PCR data were adjusted to β2-microglobulin measurements using the 2−ΔΔCt method (28).

Microarray. Global gene expression analysis was performed on 20 cDNA samples from biopsies of patients with melanoma prior and post two cycles of sorafenib/temozolomide, using the Human Gene Expression 8 × 60 K Agilent Human Microarray Kit. Functional analysis was carried out through the Ingenuity Pathway Analysis (Ingenuity System).

Statistical analyses. Differences between groups of quantitative data were assessed by Mann–Whitney U test or Wilcoxon signed-rank test for all distributions, or Student paired or unpaired t test if the criteria for Gaussian distribution was met. All reported P values were two-sided, and a P value of less than 0.05 was considered statistically significant.

Results. Effector memory CD4+ NKG2D+ T cells in metastatic melanoma patients. In accordance with a previous report (9), the sorafenib and temozolomide combination therapy (schedule summarized in Supplementary Fig. S1) induced one complete response (CR), four partial responses (PR), and 21 disease stabilizations (SD).

www.aacjrournals.org Cancer Res; 74(1) January 1, 2014 71

Sorafenib Regulates IL-15Rα and NKG2D Ligands

Downloaded from cancerres.aacrjournals.org on April 15, 2017. © 2014 American Association for Cancer Research.
Figure 1. Increase of CD4⁺ NKG2D⁺ T cells exhibiting an TEm phenotype. A, flow cytometry analyses of NKG2D expression on freshly isolated subsets of circulating lymphocytes [CD3⁺CD8⁺ (left), CD3⁺CD56⁺ (middle), and CD3⁺CD4⁺ (right)] in metastatic melanoma before (0) and after one to two cycles (1, 2) of therapy as well as in sex- and age-matched healthy volunteers (HV). Each dot represents 1 patient or healthy volunteer. Intraindividual variations between pre- and posttherapy are analyzed by paired Student t test (*, P < 0.05; **, P < 0.01). B, flow cytometry analyses of NKG2D expression according to CD4 and CD8 expression. NKG2D expression on CD4⁺ T cells proportional to the staining with anti-CD8 mAb shown in a representative histogram (right). C and D, phenotyping of CD4⁺ NKG2D⁺ T cells recovered from metastatic melanoma at diagnosis according to CD45RA and CCR7 expression (C) or from 11 patients with metastatic melanoma in a kinetic study according to various NK cell receptors (D). Student t test to compare CD4⁺ NKG2D⁺ or NKG2D⁺ T cells; ***, P < 0.001. Intraindividual variations between pre- and posttherapy are analyzed by Wilcoxon signed-rank test (ns, not significant).
Sorafenib Regulates IL-15Rα and NKG2D Ligands

Figure 2. Phenotype of CD4\(^+\) NKG2D\(^+\) tumor-infiltrating lymphocytes in metastatic melanoma. A, flow cytometry analyses of CD4\(^+\) CD3\(^+\) CD4\(^-\) infiltrating lymphocytes in blood, noninvaded lymph node (Non-met LN), lymph node metastasis (Met LN), or other metastatic tissue (Met). A representative dot plot is shown with the percentages of NKG2D\(^+\) cells among the CD4\(^+\) T-cell population (left two). In 9 cases, paired specimen [cubing blood or noninvaded lymph node to tumor beds (Met lymph node or Met)] were examined (connected lines, right). Wilcoxon signed-rank test showed no statistical significance (ns). B and C, expression of PD-1 and Tim-3 on CD4\(^+\) CD3\(^+\) CD4\(^-\) tumor-infiltrating lymphocytes (Met LN) versus PBMCs (Blood) based on NKG2D expression. A representative dot plot (B) is shown and the results from 9 Met lymph nodes are depicted in the graph (C). Student t test was used to compare CD4\(^+\) NKG2D\(^+\) and NKG2D\(^+\) T cells; *, *P < 0.05; ns, not significant.

Figure 3. Synergistic effects of TCR, CD122, and NKG2D engagement for Th1 polarization in CD4\(^+\) NKG2D\(^+\) T cells. A, TCR and NKG2D-dependent Th1 cytokine release by CD4\(^+\) NKG2D\(^+\) T cells. Cytokine release was measured using ELISA for human IFN-\(\gamma\), IL-2, and TNF-\(\alpha\) in the supernatants of circulating CD4\(^+\) T cells recovered before therapy in 4 patients with metastatic melanoma. Cells were stimulated overnight with a combination of suboptimal amounts of anti-CD3 (aCD3; 0.5 \(\mu\)g/mL) and anti-NKG2D (aNKG2D; 4 \(\mu\)g/mL) antibodies. IL-17 and IL-10 were not detectable in these conditions (not shown). The graph depicts the means ± SEM of cytokine release from four metastatic melanoma (each one being tested in triplicate wells). The synergistic effect of aCD3 + aNKG2D was tested by Student t test (*, *P < 0.05). B, cytokine production, gating on CD4\(^+\) NKG2D\(^+\) (top) and CD4\(^+\) NKG2D\(^+\) (bottom) at 48 hours of stimulation using flow cytometry and intracellular stainings. A representative dot plot is depicted. C, the synergistic effect of CD122 triggering (dose response of cross-linked anti-CD122 agonistic antibody) together with TCR/NKG2D engagement on cell-sorted CD4\(^+\) NKG2D\(^+\) or NKG2D\(^+\) T cells from 3 patients with metastatic melanoma. Data from one representative patient show the percentage of IFN-\(\gamma\)\(^+\) cells assessed by flow cytometry and intracellular staining.
Figure 4. Sorafenib-induced cell surface expression of IL-15Rx and downregulation of MICA/B. A, downregulation of MICA/B expression on melanoma cell lines in vitro. Flow cytometry analysis of MICA/B expression at 48 hours after exposure to sorafenib at increasing concentrations gating on live MEL10 and MEL888 cells. FMO-control is indicated in thin black line. Representative overlays are shown. B, hematoxylin and eosin (H&E) staining of metastatic melanoma lesions and immunofluorescence using anti-IL-15Rx antibodies. Nuclei are visualized with a DAPI (blue) staining, whereas melanoma plasma membrane appears in red (staining with secondary anti-goat IgG Alexa Fluor 568 recognizing the anti-IL-15Rx antibody). Two representative patients’ paired lesions (pre- and posttherapy) are shown. Right, graph representative of 8 independent tumor lesions examined before and after therapy, showing the percentage of positivity. C, RT-PCR determinations of the relative expression of the IL-15Rx gene in 20 paired metastatic melanoma lesions before and after three cycles of therapy. (Continued on the following page.)
at 3 months (CR + PR + SD called hereafter "responders") and 37 progressive disease being referred to as "nonresponders" according to the RECIST criteria (Table 1). Severe lymphopenia was observed in both responders and nonresponders (Supplementary Fig. S2A and S2B).

We phenotyped circulating lymphocytes in a longitudinal study over 2 months in 63 patients included in this phase I/II trial. All patients with metastatic melanoma showed a significant reduction of NKG2D expression in both CD8⁺ T and NK cells at diagnosis compared with healthy volunteers (Fig. 1A). Conversely, there was a higher proportion of CD4⁺ T cells expressing NKG2D in all patients with metastatic melanoma compared with healthy volunteers (Fig. 1, A and B). These CD4⁺ NKG2D⁺ T cells differed from the CD4⁺ NKG2D⁺ T-cell subset in that they coexpressed low levels of CD69 (Fig. 1B) and exhibited an effector memory (TEM; CD45RA⁻CCR7⁺) phenotype (Fig. 1C). Extensive phenotyping showed that about 20% of CD4⁺ NKG2D⁺ T cells expressed the C-type lectin receptor NKR-P1A (CD161) as described by others (29), but failed to express other NK receptors (such as 2B4, KIR, NCR, and CD94/NKG2A) in contrast to previously described CD4⁺ NKG2D⁺ T cells (Fig. 1D; ref. 30). Finally, CD4⁺ NKG2D⁺ T cells did not express the fractalkine receptor CX3CR1 associated with T-cell trafficking into tumor beds (Fig. 1D).

Lymph node resection in high-grade melanoma allowed us to examine the capacity of CD4⁺ NKG2D⁺ T cells to traffic to tumor beds. Indeed, this subset represented up to 2% to 25% of the CD4⁺ tumor-infiltrating lymph node T cells (Met lymph node), generally not enriched compared with blood or nonmetastatic lymph node (non-Met lymph node; when paired specimen were available; Fig. 2A), and expressed higher levels of PD-1 (but similar levels of TIM-3) molecules compared with CD4⁻ NKG2D⁺ T cells (Fig. 2B and C). Of note, these Met lymph node contained about 73% ± 20% of CD4⁺ cells.

Altogether, the regulation of NKG2D expression in CD4⁺ versus CD8⁺ or NK cells is uncoupled in patients with metastatic melanoma. The accumulation of CD4⁺ CD69⁺ or CD4⁺ NKG2D⁺ T-cell subset in blood (and tumors) is frequently observed in melanoma but can also be found in other malignancies (Supplementary Fig. S3).

**Th1 polarization of CD4⁺ NKG2D⁺ T cells upon engagement of NKG2D and CD122**

First, we analyzed the capacity of CD4⁺ T cells to secrete cytokines after engagement of the T-cell receptor (TCR) and/or NKG2D before therapy. A strong synergistic effect on the production of IFN-γ, IL-2, and TNF-α was observed when both receptors were triggered (Fig. 3A) in responders as well as in nonresponders (not shown). Importantly, upon TCR and NKG2D triggering, this subset failed to produce IL-17 or IL-10 (not shown). Intracellular staining revealed that most CD4⁺ NKG2D⁺ T cells produce both IFN-γ and TNF-α (Fig. 3B). Because IL-15 has been shown to be a key factor in arming an NKG2D-dependent activation of TCRαβ CTLs in celiac disease (31), we addressed whether purified CD4⁺ NKG2D⁺ T cells could be activated by coengagement of NKG2D and/or CD122 (IL-2Rβ common to both IL-2R/IL-15 signaling) with a suboptimal cross-linking of CD3 molecules. Although CD4⁺ NKG2D⁺ T cells failed to release IFN-γ upon receptor engagement, cellsorted CD4⁺ NKG2D⁺ T cells produced high levels of Th1 cytokines after a combined stimulation through TCR, CD122, and NKG2D (Fig. 3C). To further characterize the functions of these cells, we performed three additional assays (Supplementary Fig. S4). First, we incubated the NKG2D⁺ or NKG2D⁻ cell subset with soluble MICA (sMICA; expected to trigger NKG2D) and rhlL-15 (expected to stimulate IL-2Rβγ) in vitro in the presence or absence of a TCR engagement. Interestingly, sMICA + rL-15 could independently of TCR engagement synergistically induce IFN-γ secretion in the CD4⁺ NKG2D⁺ T-cell subset (as in NK cells) but not in CD4⁻ NKG2D⁻ T cells (Supplementary Fig. S4A). However, proliferation of either NKG2D⁺ or NKG2D⁻ CD4⁺ T cells could only be induced after CD3 cross-linking (Supplementary Fig. S4B). In contrast to their NKG2D⁻ counterparts, the CD4⁺ NKG2D⁺ effectors were also able to recognize and kill melanoma cells (MEL10 cell line) after IL-15 priming (Supplementary Fig. S4C). Sorafenib exposure did not enhance their cytotoxicity, which might be explained by the reported direct inhibitory activity of sorafenib on T-cell functions (32). Moreover, as shown in Fig. 4, IL-15Rα expression was only weakly increased (Fig. 4D) on the cell surface of MEL10 cells by sorafenib treatment (Fig. 4E), which could explain why the addition of IL-15 to engage CD122 was mandatory for the MEL10 cell line. To follow up on this, we then switched to the melanoma cell line MEL888, of which sorafenib had shown greater impact on the expression of IL-15Rα both on mRNA levels and cell surface (Fig. 4E and D), and tested the activation of CD4⁺ NKG2D⁺ T cells without the addition of exogenous rhlL-15 in the presence of sorafenib-treated or -untreated MEL888 cells. The result showed that CD4⁺ NKG2D⁺ T cells could only secrete IFN-γ in the presence of sorafenib-treated MEL888 cells (Supplementary Fig. S4D).

Thus, CD4⁺ NKG2D⁺ T lymphocytes constituted an TEM Th1-polarized T-cell subset capable of releasing cytokines upon TCR engagement with a strong costimulatory activity of the NKG2D receptor or upon coengagement of CD122 and NKG2D receptors.

(Continued)
Regulation of IL-15Rα expression by sorafenib in tumor beds

We analyzed how sorafenib or temozolomide could modulate the expression of the ligands for these receptors in vitro and in vivo. Lymph node–residing melanoma was reported to express low levels of NKG2D ligands (33). We analyzed sixteen "paired" but independent tumors (mostly from subcutaneous lesions), before and after three cycles of therapy by immunohistochemistry of paraffin-embedded melanoma. First, anti-CD3, -CD4, and -CD8 antibody stainings revealed abundant infiltrates that were not significantly altered by therapy (Table 2 and Supplementary Figs. S5 and S6). Of note, no staining was observed in the epidermal or mesenchymal cells of normal skin adjacent to the melanoma (not shown). The expression of MICA/B proteins was maintained by the therapy in tissue sections (Table 2) although sorafenib could, with increasing concentrations, downregulate MICA expression on melanoma cell lines in vitro, especially on MEL888 cells (Fig. 4A). Note that the MEL888 cells with 10 μmol/L sorafenib for 24 hours led to the release of sMICA/B in the supernatant (not shown).

We also monitored the IL-15Rα expression on tumor cells. Immunofluorescence analyses of paired melanoma pre- and posttherapy using anti-IL-15Rα–specific antibodies revealed that in most cases (7 of 8 patients), therapy increased cell-surface expression of IL-15Rα on tumor cells (Fig. 4B). RT-PCR analyses of 20 tumor biopsies compared the relative expression of the IL-15Rα gene pre- versus posttherapy and confirmed, in 4 cases, the upregulation of transcription or a strong and stable basal expression in 2 cases (Fig. 4C). Corroborating these data, sorafenib induced cell-surface expression of IL-15Rα and enhanced transcription of IL-15Rα in melanoma lines in vitro (Fig. 4D). Note that temozolomide was not able to induce IL-15Rα expression in vitro and did not inhibit IL-15Rα expression induced by sorafenib (not shown). Interestingly, B-RAF or c-KIT inhibitors ( vemurafenib or imatinib) failed to modulate IL-15Rα in melanoma cell lines in vitro (Fig. 4E). Monitoring of IL-15Rα on peripheral blood CD14+ cells at baseline and after two cycles of treatment revealed an upregulation preferentially in responding patients (Fig. 4F), and in patients with longer OS (over the median time of survival, 224 days; P = 0.03 with Wilcoxon signed-rank test; data not shown).

Microarray analysis was performed on 20 paired biopsies before (day 0) and after treatment (day 21) from 20 patients by establishing the log ratio (day 21/day 0) to identify genes that could be modified by the treatment regardless of the clinical response. This analysis revealed a cluster of genes among which IL-15, STAT5, and STAT1 appeared to be modulated by the treatment regardless of the clinical response evaluated at 2 months and OS. None of these parameters was associated with clinical response at any time points (Supplementary Fig. S2C and data not shown).

To conclude, sorafenib alone or combined with temozolomide may induce membrane expression of IL-15Rα in vitro and in vivo in patients with melanoma.

Increase of CD4+ NKG2D+ T cells associated with OS

Given the sorafenib-induced accumulation of CD4+ NKG2D+ Th1 cells and IL-15Rα expression in melanoma lesions, we hypothesized that this subset could influence therapeutic outcome. We analyzed potential correlations between the frequencies of CD4+NKG2D+ T, CD8+NKG2D+ T cells, and CD56+NKG2D+ NK cells at various time points with the clinical response evaluated at 2 months and OS. None of these parameters was associated with clinical response at any time points (Supplementary Fig. S2C and data not shown). However, lymphopenia at baseline influenced OS. Considering that median survival of the whole cohort is 227 days, patients...

Table 2. Semiquantitative assessment of CD3, CD4, CD8, and MICA infiltrates by IHC

<table>
<thead>
<tr>
<th>Patients</th>
<th>Clinical response</th>
<th>Before therapy</th>
<th>After therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>CD3</td>
<td>CD4</td>
</tr>
<tr>
<td>13</td>
<td>R</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>26</td>
<td>R</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>34</td>
<td>NR</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>39</td>
<td>NR</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>40</td>
<td>R</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>41</td>
<td>R</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>47</td>
<td>NR</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>48</td>
<td>NR</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>49</td>
<td>NR</td>
<td>+</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: R, responder; NR, nonresponder.
aInclusion number.
bStaining estimations assessed by two independent pathologists: -, no staining; +/−, weak; +, intermediate; ++, strong.
with prolonged survival (>227 days) exhibited higher lymphocyte counts at baseline compared with rapidly progressive patients (Fig. 5A). Importantly, the increase of circulating CD4+ NKG2D+ T cells at two cycles of therapy was associated with prolonged survival, whereas the parallel decrease of CD8+ NKG2D+ or CD56+ NKG2D+ NK cells was not (Fig. 5B and C and Supplementary Fig. S2D). The elevation of CD4+ NKG2D+ T-cell subset observed post-sorafenib (combined with temozolomide) was not apparent after miscellaneous lines of conventional therapies (including DTIC, fotemustine, isolated limb perfusion, vaccines) where long-term or short-term survivors had no more than 2.5% to 3% of CD4+ NKG2D+ T cells (Fig. 5D). Altogether, it is tempting to speculate that the accumulation of CD4+ NKG2D+ Th1 cells may be regulated by a therapy facilitating the exposure of IL-15Rα on tumor cells and/or circulating monocytes.

**Discussion**

Here, we report the first demonstration that sorafenib (combined with temozolomide) could (i) increase the proportion of a rare subset of TEM CD4+ NKGD2+ Th1 cells, and (ii) induce the upregulation of IL-15Rα on monocytes and/or in tumor sections. NKG2D ligands along with the therapeutic induction of IL-15Rα expression on the plasma membrane of tumor cells (and/or monocytes) can restore/favor the activation of tumor-infiltrating effector lymphocytes. We show that these molecules are either detectable at baseline (MICA expression) or induced by sorafenib (IL-15Rα) in metastatic melanoma where a subpopulation of rare CD4+ T cells expressing NKG2D is abnormally represented (compared with healthy volunteers). This subset can be induced to proliferate after engaging TCR and NKG2D receptors and to release Th1 cytokines after engaging CD122 and NKG2D receptors.

Several subsets of CD4+ NKG2D+ T cells have been described. First, in patients with cancer, tumor expression and shedding of sMICA/B ligand of NKG2D drove the proliferation of a CD4+ NKG2D+ T cell population that produced IL-10, TGF-β, and FasL (34, 35). The expansion of these cells inhibited bystander CD8+ and CD4+ T-cell proliferation *ex vivo*. The same autoreactive T-cell subset was inversely correlated with disease activity in autoimmune diseases (such as juvenile-onset systemic lupus erythematosus). In this report, sMIC serum levels were also inversely correlated with disease activity (36). Second, in contrast to this “regulatory” phenotype, a “proinflammatory” and cytolytic CD4+ NKG2D+ T-cell subtype has been described in autoinflammatory diseases such as Wegener’s granulomatosis (37, 38), rheumatoid arthritis (39), and Crohn’s disease (40). In most of these reports, CD4+ NKG2D+ T cells harbor an effector-memory phenotype and express many other NK-cell activating receptors (such as 2B4, DNAM-1, and CRACC) likely contributing to pathogenesis. Indeed, coligation of 2B4 in combination with DNAM-1 or NKG2D enhanced CD4+ CD28– T-cell degranulation and IFN-γ secretion engaged through suboptimal TCR triggering (30). Those TEM CD4+ NKG2D+ T cells were found in Wegener...
granulomata in close association with MIC+ and IL-15+ cells and CD208 dendritic cells (37). It is known that IL-15 upregulates NKGD2 expression on T cells and MIC expression on inflamed tissues and drives Tm differentiation and proliferation, culminating in exacerbation of autoimmune diseases (39, 41). Meresse and colleagues elegantly demonstrated in CD8+ T cells that dysregulated IL-15 expression promotes the NKGD2/DAP10 signaling pathway leading to CTL cytotoxic activity independently of the engagement of the TCR, transforming CTL into “LAK-like”LAK-like cells (31). As for CD8+ T cells, lamina propria CD4+ T cells from Crohn’s disease expressing NKGD2, Th1 cytokines, and perforin were functionally active through MICA/NKG2D interactions (40). Third, an increased frequency of double-positive CD4+CD8+ T cells was reported in Hodgkin lymphoma, human breast cancer pleural effusions (29), and in melanoma (42). However, these DP cells express high levels of CD8ββ, low levels of CD4, and produce Th2 cytokines upon HLA class I-restricted recognition of tumor cells and normal cells, suggesting that they are “regulatory” CD8+ T cells specific for self-antigens. Fourth, Maccioli and colleagues characterized CD4- and CD8- T cell clones from melanoma lesions for their dependency on TCR versus NKGD2 in the recognition patterns of melanoma cells. Very few T-cell clones were CD4- NKGD2+ and they recognized tumor cells mainly in a MHC class II-dependent fashion. Moreover, MICA/B expression was rather low in lymph node melanoma, whereas ULBP-2 was more prominent and functionally relevant (33). In our report, CD4+ NKGD2+ T cell shared biologic and functional features with proinflammatory CD4+ NKGD2+ T cells. Indeed, the CD4+ NKGD2+ T-cell subset that we observed in these patients with metastatic melanoma were enriched with Tm cells, expressed low levels of CD8ββ and high levels of CD4, secreted Th1 cytokines, and could proliferate upon suboptimal TCR triggering along with NKGD2 and/or CD122 engagement. The major difference is the lack of NK cell receptor expression. Only NKGD2 and CD161 (29, 41–44) were expressed in this cohort CD4+ NKGD2+ T cells.

The proof-of-principle that CD4+ T cells can be therapeutically harnessed against metastatic melanoma has been brought up by Hunder and colleagues, where they used IL-2 and IL-7 to differentiate tumor-specific CD4+ T cells (43). Others have found that naive CD4+ T cells after adoptive T-cell transfer can be cytotoxic and highly contribute to tumor rejection (45). Such efficient T-cell response strongly relied upon lymphopenia and common γ chain (such as IL-15). Furthermore, an appropriate dendritic cell or monocyte/CD4+ T-cell cross-talk will lead to both IL-15-driven IL-12 production by dendritic cell, and enhanced proliferation and polarization of Th1 cells (46). Cytokine/antibody immune complexes to IL-15 or IL-2 or IL-7 may mimic the effects of lymphopenia required for such an efficient triggering of naive CD4+ T cells. Therefore, it is likely that the combination of temozolomide and sorafenib, through prolonged lymphopenia, may foster an environment for the proper polarization and expansion of effector CD4+ T cells in a tumor milieu providing the right costimulatory molecules (IL-15Rα and MICA/B). Supporting this premise, our transcriptional profiling indicates that the IL-15/IL-15Rα signaling pathway and Th1 signatures are induced in lesions posttherapy (Supplementary Fig. S6).

In the absence of IL-15Rα induction, however, many strategies could be envisaged to compensate these patients. Cis- or trans-stimulating IL-2Rβγy through stabilized IL-15–based approaches have been tested in preclinical models (47). Indeed, IL-15/IL-15Rα–Fc, IL-15/IL-15Rα fusion proteins, IL-15 fused to the human antibody fragment (scFv) specific of a tumor antigen or the tumor stromal fibroblast activation protein, IL-15 gene therapy (such as the hydrodynamic injection of plasmids encoding IL-15 or IL-15 engineered oncolytic viruses) have all been reported to be efficient against mouse tumors.

Our data suggest that a subset of CD4+ T cells (expressing NKGD2) becomes biologically significant in that they may be engaged by IL-15Rα and MICA/B expressed on tumor cells and/or monocytes (either through sorafenib or spontaneously, respectively) to secrete high levels of Th1 cytokines. We cannot exclude that other NKGD2–expressing effectors could be implicated as we could also monitor CD8+ T cells infiltrating tumors. However, it seems that only CD4+ NKGD2+ T cells could be augmented after two cycles of therapy, which turned out to be clinically relevant and associated with longer OS.

In conclusion, our data suggest that CD4+ NKGD2+ T cells could be tuned functionality by induction of IL-15Rα. This observation could have some clinical impact, as compounds inducing or mimicking IL-15 transpresentation are currently under development for the treatment of cancer.

Disclosure of Potential Conflicts of Interest
C. Robert is a consultant/advisory board member of Roche, GlaxoSmithKline, Bristol-Myers Squibb, Merck, and Novartis. No potential conflicts of interest were disclosed by the other authors.

Authors’ Contributions
Conception and design: A.I. Romero, N. Chaput, C. Robert, L. Zitvogel
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): A.I. Romero, V. Pointier-Colame, S. Rusakiewicz, N. Jacquelt, K. Chaba, E. Mortier, S. Caillat-Zucman, C. Flament, M. Messaudene, P. Vielh, P. Dessen, C. Porta, C. Mateus, M. Ayyoub, D. Valmori, C. Robert
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): A.I. Romero, N. Chaput, S. Rusakiewicz, N. Jacquelt, C. Flament, A. Aupérin, M. Ayyoub, D. Valmori, L. Zitvogel
Writing, review, and/or revision of the manuscript: A.I. Romero, N. Chaput, S. Rusakiewicz, S. Caillat-Zucman, A. Caignard, M. Messaudene, P. Dessen, C. Porta, A. Eggermont, C. Robert, L. Zitvogel
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): V. Pointier-Colame, P. Vielh, L. Zitvogel
Study supervision: N. Chaput, Y. Jacquey, C. Robert, L. Zitvogel

Acknowledgments
The authors thank Bayer for providing temozolomide.

Grant Support
This work was supported by Schering-Plough legacy, Bayer Schering Pharma, Institut National du Cancer INCa, ANR, Ligue contre le cancer (équipe labellisée de L2) and INFACLARE EU grant, ISREC Foundation, SIBIC SOCRATIS, LABELX Oncology, PACRI network, S. Rusakiewicz and V. Pointier-Colame were supported by the Fondation pour la Recherche Medecale (FRM) and the Fondation de France respectively. A.I. Romero was supported by the Swedish Research Council.
Received May 6, 2013; revised September 19, 2013; accepted September 25, 2013; published OnlineFirst November 6, 2013.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

References


Published OnlineFirst November 6, 2013; DOI: 10.1158/0008-5472.CAN-13-1186

www.aacnjournals.org Cancer Res; 74(1) January 1, 2014 79

Downloaded from cancerres.aacrjournals.org on April 15, 2017. © 2014 American Association for Cancer Research.


Regulation of CD4+ NKG2D+ Th1 Cells in Patients with Metastatic Melanoma Treated with Sorafenib: Role of IL-15R α and NKG2D Triggering
